By inhibiting CDKs 1, 2, 5, and 9, dinaciclib reduces cell viability, induces apoptosis and cell cycle arrest in ALL and AML cell lines, also with MLL rearrangement, primary patient cells, and in vivo models [89,90,91,92]. Here, KMT2A is linked to acute myeloid leukemia.